IR-Med names co-founder Yaniv Cohen interim CEO

IR-Med, Inc. (IRME) announced that its Board of Directors appointed Yaniv Coheninterim Chief Executive Officer, effective September 14, 2026.

Rhea-AI Filing Summary

IR-Med, Inc. (IRME) announced that its Board of Directors appointed Yaniv Coheninterim Chief Executive Officer, effective September 14, 2026. Cohen, age 46, co-founded IR. Med Ltd. in 2013, has served as R&D manager and later Chief Scientific Officer, and is currently a director of the company.

The company states there is no arrangement or understanding with any other person pursuant to which Cohen was appointed and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. IR-Med has not entered into any new compensatory agreements with Cohen; he will continue under the company’s standard or previously disclosed compensation programs.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of interim CEO appointment: September 14, 2026 Interim CEO age: 46 years Year IR. Med Ltd. co-founded: 2013 +3 more

6 metrics

Effective date of interim CEO appointment September 14, 2026 Date Yaniv Cohen’s role as interim Chief Executive Officer became effective

Interim CEO age 46 years Age of Yaniv Cohen at the time of appointment

Year IR. Med Ltd. co-founded 2013 Year Yaniv Cohen co-founded IR. Med Ltd.

Medical device patents held 4 patents Number of medical device patents held by Yaniv Cohen

Scientific articles co-authored 8 articles Number of scientific journal articles co-authored by Yaniv Cohen

Service as PIMS R&D manager 2010–2013 Period Cohen served as R&D manager at PIMS, an Israeli medical device company

Key Terms

interim Chief Executive Officer, Emerging growth company, Item 404(a) of Regulation S-K, Board of Directors

4 terms

interim Chief Executive Officer financial

"appointed Yaniv Cohen, as interim Chief Executive Officer of the Company"

An interim chief executive officer is a temporary leader appointed to run a company while the board searches for a permanent CEO or manages an unexpected departure. Investors pay attention because this person shapes near-term strategy, stability and market confidence—like a substitute driver steering the car until the regular driver returns—and their actions and credibility can influence share price, hiring and major deals.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Item 404(a) of Regulation S-K regulatory

"no transactions in which Mr. Cohen has an interest requiring disclosure under Item 404(a) of Regulation S-K"

Board of Directors financial

"the Board of Directors (the “Board”) of IR-Med, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership change did IRME announce on September 14, 2026?

IR-Med, Inc. appointed Yaniv Cohen as interim Chief Executive Officer, effective September 14, 2026. He is a co-founder of IR. Med Ltd., has served as R&D manager and Chief Scientific Officer, and is currently a member of the Board of Directors.

What is Yaniv Cohen’s background relevant to his interim CEO role at IRME?

Yaniv Cohen, age 46, co-founded IR. Med Ltd. in 2013, served as R&D manager and later CSO, holds four patents in medical devices, has co-authored eight scientific articles, and has prior engineering roles at PIMS, Cisco, and Intel Israel.

Did IRME enter a new compensation agreement with interim CEO Yaniv Cohen?

No. IR-Med states it has not entered into any new compensatory arrangements or amendments with Yaniv Cohen in connection with his appointment as interim CEO. He will continue to participate in the company’s standard or previously disclosed compensation programs.

Are there related-party transactions involving IRME’s interim CEO that require disclosure?

IR-Med reports that there are no transactions in which Yaniv Cohen has an interest requiring disclosure under Item 404(a) of Regulation S-K, other than what is described in the announcement of his appointment.

Is Yaniv Cohen’s appointment as IRME interim CEO linked to any special arrangement?

The company states there is no arrangement or understanding between Yaniv Cohen and any other person pursuant to which he was appointed interim Chief Executive Officer, apart from what is described in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:06 PM Accepted by SEC EDGAR 09/15/2026 - 04:05 PM Learn about SEC filing dates

false 0001839133 0001839133 2026-09-14 2026-09-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 14, 2026

IR-MED, INC.

Nevada		000-56492		84-4516398
(State or Other Jurisdiction		(Commission		(IRS Employer
Of incorporation)		File Number)		Identification Number)

ZHR Industrial Zone Rosh Pina Israel		1231400
(Address of Principal Executive Offices)		(Area Code)

+ 972-4-655-5054

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 14, 2026, the Board of Directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Yaniv Cohen, as interim Chief Effective Officer of the Company, effective as of September 14, 2026.

Mr. Cohen, age 46, co-founded IR. Med Ltd. in September 2013 and has served as the R&D manager. Following the completion of the acquisition of IR. Med Ltd he serves as the CSO. and was appointed to the Board. Mr. Cohen is an experienced electrical engineer with expertise in the fields of wave propagation and IR Spectroscopy for medical applications. Additionally, Mr. Cohen holds four patents in medical devices, has co-authored eight articles in scientific journals, and has spoken in conferences around the globe. From 2010 to 2013, Mr. Cohen served as R&D manager for PIMS, an Israeli medical device company, focusing on IR imaging and spectral analysis for non-invasive cancer assessment and identification. From 2008 to 2009, Mr. Cohen worked for Cisco as a system engineer. From 2006 to 2008, he worked as a service engineer for Intel Israel. Since 2022, Mr. Cohen holds a Ph.D of Sciences in the doctoral program, Informatics and Computer Engineering in the National Research University Higher School of Economics, School of Electronic Engineering Institute of Electronics and Mathematics (MIEM HSE) in Moscow, Russia. Mr. Cohen holds a M.Sc. in Electrical Engineering from Holon Institute of Technology (2007). From 2009 to 2010, he attended the Ben-Gurion University of the Negev, Beer Sheva, Israel where he wrote a thesis in wave prorogation.

Except as otherwise set forth herein, there is no arrangement or understanding between Mr. Cohen and any other person pursuant to which he was appointed as interim Chief Executive Officer and there are no transactions in which Mr. Cohen has an interest requiring disclosure under Item 404(a) of Regulation S-K.

In connection with Mr. Cohen’s appointment as Interim Chief Executive Officer, the Company has not entered into any new compensatory arrangements or agreements, nor have any amendments been made to existing compensatory arrangements with Mr. Cohen at this time. Mr. Cohen will continue to participate in the standard compensation programs available to the Company’s non-employee directors, if applicable, or as otherwise previously disclosed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IR-Med, Inc.
	By:	/s/ Sharon Levkoviz
	Name:	Sharon Levkoviz
	Title:	Chief Financial Officer

Date: September 15, 2026

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB